Cargando…
A single center clinical analysis of children with high-risk neuroblastoma
The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions. We aimed to assess the protocol formulated by Chinese Children’s Cancer Group study in 2009, and the impac...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444748/ https://www.ncbi.nlm.nih.gov/pubmed/28423674 http://dx.doi.org/10.18632/oncotarget.15996 |
_version_ | 1783238757984501760 |
---|---|
author | Tian, Xiangdong Cao, Yanna Wang, Jingfu Yan, Jie Tian, Yao Li, Zhongyuan Wang, Huijuan Duan, Xiaofeng Jin, Yan Zhao, Qiang |
author_facet | Tian, Xiangdong Cao, Yanna Wang, Jingfu Yan, Jie Tian, Yao Li, Zhongyuan Wang, Huijuan Duan, Xiaofeng Jin, Yan Zhao, Qiang |
author_sort | Tian, Xiangdong |
collection | PubMed |
description | The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions. We aimed to assess the protocol formulated by Chinese Children’s Cancer Group study in 2009, and the impact of surgery extent was highlightly evaluated. METHODS: This study enrolled patients with high-risk neuroblastoma between 2009 and 2014 in Department of Pediatric Oncology of Tianjin Medical University Cancer Institute and Hospital. The clinical characteristics of patients were illustrated and surgery extent was evaluated by the impact on survival rate. RESULTS: The 3-year overall survival (OS) and progression-free survival (PFS) were 56.2% and 50.5%, respectively. LDH (P<0.001), bone marrow metastasis at time of diagnosis (P=0.001), bone marrow negative after neoadjuvant chemotherapy (P<0.001), radiotherapy (P<0.001) were significant predictors of OS and PFS. And surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time. CONCLUSIONS: This study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients received subtotal tumor resection. Longer term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy. |
format | Online Article Text |
id | pubmed-5444748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54447482017-06-01 A single center clinical analysis of children with high-risk neuroblastoma Tian, Xiangdong Cao, Yanna Wang, Jingfu Yan, Jie Tian, Yao Li, Zhongyuan Wang, Huijuan Duan, Xiaofeng Jin, Yan Zhao, Qiang Oncotarget Research Paper The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions. We aimed to assess the protocol formulated by Chinese Children’s Cancer Group study in 2009, and the impact of surgery extent was highlightly evaluated. METHODS: This study enrolled patients with high-risk neuroblastoma between 2009 and 2014 in Department of Pediatric Oncology of Tianjin Medical University Cancer Institute and Hospital. The clinical characteristics of patients were illustrated and surgery extent was evaluated by the impact on survival rate. RESULTS: The 3-year overall survival (OS) and progression-free survival (PFS) were 56.2% and 50.5%, respectively. LDH (P<0.001), bone marrow metastasis at time of diagnosis (P=0.001), bone marrow negative after neoadjuvant chemotherapy (P<0.001), radiotherapy (P<0.001) were significant predictors of OS and PFS. And surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time. CONCLUSIONS: This study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients received subtotal tumor resection. Longer term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy. Impact Journals LLC 2017-03-07 /pmc/articles/PMC5444748/ /pubmed/28423674 http://dx.doi.org/10.18632/oncotarget.15996 Text en Copyright: © 2017 Tian et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Tian, Xiangdong Cao, Yanna Wang, Jingfu Yan, Jie Tian, Yao Li, Zhongyuan Wang, Huijuan Duan, Xiaofeng Jin, Yan Zhao, Qiang A single center clinical analysis of children with high-risk neuroblastoma |
title | A single center clinical analysis of children with high-risk neuroblastoma |
title_full | A single center clinical analysis of children with high-risk neuroblastoma |
title_fullStr | A single center clinical analysis of children with high-risk neuroblastoma |
title_full_unstemmed | A single center clinical analysis of children with high-risk neuroblastoma |
title_short | A single center clinical analysis of children with high-risk neuroblastoma |
title_sort | single center clinical analysis of children with high-risk neuroblastoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444748/ https://www.ncbi.nlm.nih.gov/pubmed/28423674 http://dx.doi.org/10.18632/oncotarget.15996 |
work_keys_str_mv | AT tianxiangdong asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT caoyanna asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT wangjingfu asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT yanjie asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT tianyao asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT lizhongyuan asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT wanghuijuan asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT duanxiaofeng asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT jinyan asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT zhaoqiang asinglecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT tianxiangdong singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT caoyanna singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT wangjingfu singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT yanjie singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT tianyao singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT lizhongyuan singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT wanghuijuan singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT duanxiaofeng singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT jinyan singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma AT zhaoqiang singlecenterclinicalanalysisofchildrenwithhighriskneuroblastoma |